Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Operating Expenses | 17,275 | 21,643 | 16,806 | 23,088 | 17,214 |
| Operating Income | -17,275 | -21,643 | -16,806 | -23,088 | -17,214 |
| Interest Expense | 949 | 244 | 0 | 0 | 0 |
| Other Income | -77 | 2,096 | 6,798 | 5,340 | -210 |
| Pre-tax Income | -18,301 | -19,791 | -10,008 | -17,748 | -17,424 |
| Income Tax | -1,003 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -17,298 | -19,791 | -10,008 | -17,748 | -17,424 |
| Net Income | $-17,298 | $-19,791 | $-10,008 | $-17,748 | $-17,424 |
| EPS Basic Total Ops | -20.56 | -66.28 | 0.00 | -227.40 | 0.00 |
| EPS Basic Continuous Ops | -20.55 | -66.28 | -81.79 | -227.39 | -324.77 |
| EPS Diluted Total Ops | -20.56 | -66.28 | 0.00 | -227.40 | 0.00 |
| EPS Diluted Continuous Ops | -20.55 | -66.28 | -81.79 | -227.39 | -324.77 |
| EPS Diluted Before Non-Recurring Items | 0.00 | 0.00 | -0.40 | -224.00 | -328.00 |
| EBITDA(a) | $-17,275 | $-21,629 | $-16,802 | $-23,084 | $-17,210 |